#JPM23: Fire­side chat with Ei­sai's Ivan Che­ung

Less than a week af­ter Ei­sai and Bio­gen won ac­cel­er­at­ed ap­proval from the FDA for their Alzheimer’s drug lecanemab, Ex­ec­u­tive Ed­i­tor Drew Arm­strong spoke one-on-one with Ei­sai’s US CEO Ivan Che­ung, who al­so leads the com­pa­ny’s Alzheimer’s ef­forts. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

Drew Arm­strong:

Wel­come every­body. I am Drew Arm­strong, the ex­ec­u­tive ed­i­tor over at End­points News, and I’m ex­cep­tion­al­ly pleased to be joined by Ivan Che­ung from Ei­sai. He runs the US busi­ness and over­sees the Alzheimer’s pro­gram there. Ob­vi­ous­ly, you all have had some enor­mous news in the last week with the ac­cel­er­at­ed ap­proval of Lecanemab, and con­grat­u­la­tions on that. It’s ob­vi­ous­ly a huge mo­ment for the field, huge mo­ment for your com­pa­ny. I want to jump right in be­cause we have 30 min­utes and so much to cov­er. I’m in­cred­i­bly ex­cit­ed to get this chance to talk to you. Now, that I’m in San Fran­cis­co, you’re in New Jer­sey. I’m sor­ry we aren’t able to be to­geth­er in per­son, but tons of news from you all. You’ve got­ten this ac­cel­er­at­ed ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER